STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more
STAT
MAY 3, 2024
Back in 2004, Gilead explained its decision by maintaining the medicines were not sufficiently different, but internal documents produced in court suggested the company made this move in order to maximize profits. Topline data are expected late this year. Continue to STAT+ to read the full story…
Let's personalize your content